What does section 13 of the Hazard Product Labeling cover?

Section 13 of the Hazard Product Labeling focuses specifically on the risks associated with hazardous substances, particularly in relation to their potential to cause cancer (carcinogenicity), genetic mutations (genotoxicity), and developmental abnormalities in embryos or fetuses (teratogenicity). This section provides critical information that helps users understand the health risks associated with exposure to specific chemicals, enabling them to take appropriate precautions.

This content is vital for individuals who handle hazardous materials, as it supports informed decision-making on safety measures and risk mitigation. In a laboratory or compounding pharmacy setting, being aware of these specific hazards allows technicians to implement proper safety protocols and ensure a safe working environment, especially when working with substances known to have severe health consequences.

In contrast, the other options cover different aspects of hazard labeling, such as general handling precautions, product identification, or first aid measures, which are important but do not focus specifically on the toxicity risks outlined in section 13. Thus, the emphasis on carcinogenicity, genotoxicity, and teratogenicity is what makes this option the correct choice.